Abstract:The underlying mechanisms of polycystic ovarian syndrome (PCOS)-induced endometrial dysfunction are not fully understood, and although accumulating evidence shows that the use of metformin has beneficial effects in PCOS patients, the precise regulatory mechanisms of metformin on endometrial function under PCOS conditions have only been partially explored. To address these clinical challenges, this study aimed to assess the protein expression patterns of glycolytic enzymes, estrogen receptor (ER), and androgen receptor (AR) along with differences in mitochondria-dependent apoptosis in PCOS patients with and without endometrial hyperplasia in vivo and to investigate the effects of metformin in PCOS patients with endometrial hyperplasia in vitro. Here, we showed that compared to non-PCOS patients and PCOS patients without hyperplasia, the endometria from PCOS patients with hyperplasia had a distinct protein expression pattern of glycolytic enzymes, including pyruvate kinase isozyme M2 isoform (PKM2) and pyruvate dehydrogenase (PDH), and mitochondrial transcription factor A (TFAM). In PCOS patients with endometrial hyperplasia, increased glandular epithelial cell secretion and infiltrated stromal cells in the glands were associated with decreased PDH immunoreactivity in the epithelial cells. Using endometrial tissues from PCOS patients with hyperplasia, we found that in response to metformin treatment in vitro, hexokinase 2 (HK2) expression was decreased, whereas phosphofructokinase (PFK), PKM2, and lactate dehydrogenase A (LDHA) expression was increased compared to controls. Although there was no change in PDH expression, metformin treatment increased the expression of TFAM and cleaved caspase-3. Moreover, our in vivo study showed that while endometrial ERβ expression was no different between non-PCOS and PCOS patients regardless of whether or not hyperplasia was present, ERα and AR protein expression was gradually increased in women with PCOS following the onset of endometrial hyperplasia. Our in vitro study showed that treatment with metformin inhibited ERα expression without affecting ERβ expression. Our findings suggest that decreased glycolysis and increased mitochondrial activity might contribute to the onset of ERα-dependent endometrial hyperplasia and that metformin might directly reverse impaired glycolysis and normalize mitochondrial function in PCOS patients with endometrial hyperplasia.

Metformin Inhibits Growth of Eutopic Stromal Cells from Adenomyotic Endometrium Via AMPK Activation and Subsequent Inhibition of AKT Phosphorylation: a Possible Role in the Treatment of Adenomyosis.

Metformin Inhibits 17Β-Estradiol-induced Epithelial-to-mesenchymal Transition Via Βklotho-Related ERK1/2 Signaling and AMPKα Signaling in Endometrial Adenocarcinoma Cells.

Metformin Suppresses Prostaglandin E2-Induced Cytochrome P450 Aromatase Gene Expression and Activity via Stimulation of AMP-Activated Protein Kinase in Human Endometriotic Stromal Cells

Metformin inhibits StAR expression in human endometriotic stromal cells via AMPK-mediated disruption of CREB-CRTC2 complex formation.

Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo

Metformin Inhibits Estrogen‐dependent Endometrial Cancer Cell Growth by Activating the AMPK–FOXO1 Signal Pathway

Metformin enhances epithelial cell growth inhibition via the protein kinase–insulin-like growth factor binding protein-1 pathway

Metformin is Associated with Reduced Cell Proliferation in Human Endometrial Cancer by Inbibiting PI3K/AKT/mTOR Signaling.

Metformin Regulates Stromal-Epithelial Cells Communication Via Wnt2/β-catenin Signaling in Endometriosis

Metformin-Induced Stimulation of Adenosine 5′ Monophosphate-Activated Protein Kinase (PRKA) Impairs Progesterone Secretion in Rat Granulosa Cells1

Berberine Inhibits Growth and Inflammatory Invasive Phenotypes of Ectopic Stromal Cells: Imply the Possible Treatment of Adenomyosis.

Effects of Metformin on Bovine Granulosa Cells Steroidogenesis: Possible Involvement of Adenosine 5′ Monophosphate-Activated Protein Kinase (AMPK)1

Metformin Promotes Progesterone Receptor Expression Via Inhibition of Mammalian Target of Rapamycin (mtor) in Endometrial Cancer Cells

DIFFERENT PROTEOMICS ANALYSIS INDICATES METFORMIN AS A NOVEL THERAPY TO AMELIORATE ENDOMETRIAL RECEPTIVITY OF ENDOMETRIOSIS

Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1

Metformin Inhibits Endothelial Progenitor Cell Migration by Decreasing Matrix Metalloproteinases, MMP-2 and MMP-9, Via the AMPK/mTOR/autophagy Pathway.

Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating Mtor Activity in Vitro and in Vivo.

Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer, In Vivo and the Impact of Metformin In Vitro

Metformin inhibits estradiol and progesterone-induced decidualization of endometrial stromal cells by regulating expression of progesterone receptor, cytokines and matrix metalloproteinases

Estradiol ameliorates metformin-inhibited Sertoli cell proliferation via AMPK/TSC2/mTOR signaling pathway

Inhibitory effect on proliferation induced by adiponectin in endometrial cancer cells via AMPK/ERK signaling pathway